Analysis of response evaluation criteria in solid tumors reduction ratio of primary chemotherapy in unresectable advanced or recurrent colorectal cancer

Shiho Kawagoe, Masahiro Nakano, Keita Uchino, Kohei Arimizu, Tatsuhiro Kajitani, Hozumi Shimokawa, Tetsuya Kusumoto, Koji Ikejiri, Eishi Baba

Research output: Contribution to journalArticle

Abstract

Response Evaluation Criteria in Solid Tumors (RECIST) is used to assess the objective response of solid tumors to treatment. However, it remains unclear to what extent the response rate assessed by RECIST reflects a reduction of tumor size in multiple organs in patients with unresectable advanced or recurrent colorectal cancer (CRC) with multiple organ metastases. It is also unclear whether the management of liver metastases with systemic chemotherapy in CRC patients with multiple organ metastases improves their prognosis, although surgical resection has been shown to be the most effective treatment approach to CRC cases with liver metastases. A total of 38 CRC patients who underwent systemic chemotherapy in Kyushu Medical Center Hospital between January 2013 and April 2016 were examined. The patients had measurable lesions in multiple organs, including the liver, and did not undergo curative surgery for metastatic lesions after initiation of chemotherapy. The association between the total reduction ratio (TRR) of all lesions and liver lesion reduction ratio (LRR) was retrospectively analyzed. A total of 18 patients (47%) had H3 liver metastases, and the median liver lesion occupancy rate in the sum of the measured lesions with RECIST was 76%. TRR and LRR were strongly correlated, regardless of the volume of the liver metastases. Although a TRR of >30% was significantly associated with improved overall survival (OS), this improvement was not observed in patients with H3 liver metastases. TRR was correlated with LRR and was associated with a better OS. CRC patients with both multiple organ and H3 liver metastases exhibited poor survival, even with a high reduction ratio by chemotherapy.

Original languageEnglish
Pages (from-to)243-251
Number of pages9
JournalMolecular and Clinical Oncology
Volume11
Issue number3
DOIs
Publication statusPublished - Sep 1 2019

Fingerprint

Colorectal Neoplasms
Drug Therapy
Neoplasm Metastasis
Liver
Survival
Response Evaluation Criteria in Solid Tumors
Neoplasms
Therapeutics

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Analysis of response evaluation criteria in solid tumors reduction ratio of primary chemotherapy in unresectable advanced or recurrent colorectal cancer. / Kawagoe, Shiho; Nakano, Masahiro; Uchino, Keita; Arimizu, Kohei; Kajitani, Tatsuhiro; Shimokawa, Hozumi; Kusumoto, Tetsuya; Ikejiri, Koji; Baba, Eishi.

In: Molecular and Clinical Oncology, Vol. 11, No. 3, 01.09.2019, p. 243-251.

Research output: Contribution to journalArticle

Kawagoe, Shiho ; Nakano, Masahiro ; Uchino, Keita ; Arimizu, Kohei ; Kajitani, Tatsuhiro ; Shimokawa, Hozumi ; Kusumoto, Tetsuya ; Ikejiri, Koji ; Baba, Eishi. / Analysis of response evaluation criteria in solid tumors reduction ratio of primary chemotherapy in unresectable advanced or recurrent colorectal cancer. In: Molecular and Clinical Oncology. 2019 ; Vol. 11, No. 3. pp. 243-251.
@article{b798be4e8cdf43e09f18ec332a3a7393,
title = "Analysis of response evaluation criteria in solid tumors reduction ratio of primary chemotherapy in unresectable advanced or recurrent colorectal cancer",
abstract = "Response Evaluation Criteria in Solid Tumors (RECIST) is used to assess the objective response of solid tumors to treatment. However, it remains unclear to what extent the response rate assessed by RECIST reflects a reduction of tumor size in multiple organs in patients with unresectable advanced or recurrent colorectal cancer (CRC) with multiple organ metastases. It is also unclear whether the management of liver metastases with systemic chemotherapy in CRC patients with multiple organ metastases improves their prognosis, although surgical resection has been shown to be the most effective treatment approach to CRC cases with liver metastases. A total of 38 CRC patients who underwent systemic chemotherapy in Kyushu Medical Center Hospital between January 2013 and April 2016 were examined. The patients had measurable lesions in multiple organs, including the liver, and did not undergo curative surgery for metastatic lesions after initiation of chemotherapy. The association between the total reduction ratio (TRR) of all lesions and liver lesion reduction ratio (LRR) was retrospectively analyzed. A total of 18 patients (47{\%}) had H3 liver metastases, and the median liver lesion occupancy rate in the sum of the measured lesions with RECIST was 76{\%}. TRR and LRR were strongly correlated, regardless of the volume of the liver metastases. Although a TRR of >30{\%} was significantly associated with improved overall survival (OS), this improvement was not observed in patients with H3 liver metastases. TRR was correlated with LRR and was associated with a better OS. CRC patients with both multiple organ and H3 liver metastases exhibited poor survival, even with a high reduction ratio by chemotherapy.",
author = "Shiho Kawagoe and Masahiro Nakano and Keita Uchino and Kohei Arimizu and Tatsuhiro Kajitani and Hozumi Shimokawa and Tetsuya Kusumoto and Koji Ikejiri and Eishi Baba",
year = "2019",
month = "9",
day = "1",
doi = "10.3892/mco.2019.1894",
language = "English",
volume = "11",
pages = "243--251",
journal = "Molecular and Clinical Oncology",
issn = "2049-9450",
number = "3",

}

TY - JOUR

T1 - Analysis of response evaluation criteria in solid tumors reduction ratio of primary chemotherapy in unresectable advanced or recurrent colorectal cancer

AU - Kawagoe, Shiho

AU - Nakano, Masahiro

AU - Uchino, Keita

AU - Arimizu, Kohei

AU - Kajitani, Tatsuhiro

AU - Shimokawa, Hozumi

AU - Kusumoto, Tetsuya

AU - Ikejiri, Koji

AU - Baba, Eishi

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Response Evaluation Criteria in Solid Tumors (RECIST) is used to assess the objective response of solid tumors to treatment. However, it remains unclear to what extent the response rate assessed by RECIST reflects a reduction of tumor size in multiple organs in patients with unresectable advanced or recurrent colorectal cancer (CRC) with multiple organ metastases. It is also unclear whether the management of liver metastases with systemic chemotherapy in CRC patients with multiple organ metastases improves their prognosis, although surgical resection has been shown to be the most effective treatment approach to CRC cases with liver metastases. A total of 38 CRC patients who underwent systemic chemotherapy in Kyushu Medical Center Hospital between January 2013 and April 2016 were examined. The patients had measurable lesions in multiple organs, including the liver, and did not undergo curative surgery for metastatic lesions after initiation of chemotherapy. The association between the total reduction ratio (TRR) of all lesions and liver lesion reduction ratio (LRR) was retrospectively analyzed. A total of 18 patients (47%) had H3 liver metastases, and the median liver lesion occupancy rate in the sum of the measured lesions with RECIST was 76%. TRR and LRR were strongly correlated, regardless of the volume of the liver metastases. Although a TRR of >30% was significantly associated with improved overall survival (OS), this improvement was not observed in patients with H3 liver metastases. TRR was correlated with LRR and was associated with a better OS. CRC patients with both multiple organ and H3 liver metastases exhibited poor survival, even with a high reduction ratio by chemotherapy.

AB - Response Evaluation Criteria in Solid Tumors (RECIST) is used to assess the objective response of solid tumors to treatment. However, it remains unclear to what extent the response rate assessed by RECIST reflects a reduction of tumor size in multiple organs in patients with unresectable advanced or recurrent colorectal cancer (CRC) with multiple organ metastases. It is also unclear whether the management of liver metastases with systemic chemotherapy in CRC patients with multiple organ metastases improves their prognosis, although surgical resection has been shown to be the most effective treatment approach to CRC cases with liver metastases. A total of 38 CRC patients who underwent systemic chemotherapy in Kyushu Medical Center Hospital between January 2013 and April 2016 were examined. The patients had measurable lesions in multiple organs, including the liver, and did not undergo curative surgery for metastatic lesions after initiation of chemotherapy. The association between the total reduction ratio (TRR) of all lesions and liver lesion reduction ratio (LRR) was retrospectively analyzed. A total of 18 patients (47%) had H3 liver metastases, and the median liver lesion occupancy rate in the sum of the measured lesions with RECIST was 76%. TRR and LRR were strongly correlated, regardless of the volume of the liver metastases. Although a TRR of >30% was significantly associated with improved overall survival (OS), this improvement was not observed in patients with H3 liver metastases. TRR was correlated with LRR and was associated with a better OS. CRC patients with both multiple organ and H3 liver metastases exhibited poor survival, even with a high reduction ratio by chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85071287349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071287349&partnerID=8YFLogxK

U2 - 10.3892/mco.2019.1894

DO - 10.3892/mco.2019.1894

M3 - Article

VL - 11

SP - 243

EP - 251

JO - Molecular and Clinical Oncology

JF - Molecular and Clinical Oncology

SN - 2049-9450

IS - 3

ER -